- Home
- LFCR vs RNAC Comparison
LFCR vs RNAC Comparison
Compare LFCR & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- RNAC
- Stock Information
- Founded
- LFCR 1986
- RNAC 2007
- Country
- LFCR United States
- RNAC United States
- Employees
- LFCR N/A
- RNAC N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- LFCR Health Care
- RNAC Health Care
- Exchange
- LFCR Nasdaq
- RNAC Nasdaq
- Market Cap
- LFCR 288.0M
- RNAC 276.3M
- IPO Year
- LFCR N/A
- RNAC 2016
- Fundamental
- Price
- LFCR $6.62
- RNAC $9.67
- Analyst Decision
- LFCR Buy
- RNAC Strong Buy
- Analyst Count
- LFCR 4
- RNAC 4
- Target Price
- LFCR $8.00
- RNAC $40.00
- AVG Volume (30 Days)
- LFCR 231.6K
- RNAC 81.3K
- Earning Date
- LFCR 10-03-2025
- RNAC 11-06-2025
- Dividend Yield
- LFCR N/A
- RNAC N/A
- EPS Growth
- LFCR N/A
- RNAC N/A
- EPS
- LFCR N/A
- RNAC N/A
- Revenue
- LFCR $128,867,000.00
- RNAC $1,026,000.00
- Revenue This Year
- LFCR $4.71
- RNAC N/A
- Revenue Next Year
- LFCR $10.98
- RNAC N/A
- P/E Ratio
- LFCR N/A
- RNAC N/A
- Revenue Growth
- LFCR 0.47
- RNAC N/A
- 52 Week Low
- LFCR $4.59
- RNAC $8.46
- 52 Week High
- LFCR $8.85
- RNAC $26.50
- Technical
- Relative Strength Index (RSI)
- LFCR 40.90
- RNAC 47.80
- Support Level
- LFCR $6.44
- RNAC $8.95
- Resistance Level
- LFCR $6.82
- RNAC $10.12
- Average True Range (ATR)
- LFCR 0.30
- RNAC 0.54
- MACD
- LFCR -0.02
- RNAC -0.02
- Stochastic Oscillator
- LFCR 22.13
- RNAC 48.04
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.